| human | Q5 |
| P8446 | Gateway to Research person ID | 8840EEA3-4086-4264-8D80-DB3FFF422E7D |
| P496 | ORCID iD | 0000-0001-8494-732X |
| P1153 | Scopus author ID | 7102929844 |
| P734 | family name | Pharoah | Q37452990 |
| Pharoah | Q37452990 | ||
| Pharoah | Q37452990 | ||
| P735 | given name | Paul | Q4925623 |
| Paul | Q4925623 | ||
| P106 | occupation | researcher | Q1650915 |
| P5008 | on focus list of Wikimedia project | WikiProject COVID-19 | Q87748614 |
| P21 | sex or gender | male | Q6581097 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q36021406 | 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q59349476 | A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants |
| Q28384141 | A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer |
| Q33860461 | A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival |
| Q44372847 | A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer |
| Q35327105 | A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer |
| Q92224274 | A Mendelian randomization analysis of circulating lipid traits and breast cancer risk |
| Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
| Q36749452 | A U-shaped relationship between haematocrit and mortality in a large prospective cohort study |
| Q93025301 | A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases |
| Q42676622 | A combined analysis of genome-wide association studies in breast cancer |
| Q104471089 | A combined proteomics and Mendelian randomization approach to investigate the effects of aspirin-targeted proteins on colorectal cancer |
| Q57250674 | A common coding variant in CASP8 is associated with breast cancer risk |
| Q35755874 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer |
| Q45181384 | A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability |
| Q36136695 | A common variant of the p16(INK4a) genetic region is associated with physical function in older people |
| Q35957063 | A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density |
| Q34115258 | A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes |
| Q70462477 | A genetic risk score to guide age-specific, personalized prostate cancer screening |
| Q96683163 | A genetic risk score to personalize prostate cancer screening, applied to population data |
| Q39200585 | A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity |
| Q37332232 | A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk |
| Q34613513 | A genome-wide association scan on estrogen receptor-negative breast cancer |
| Q33747778 | A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. |
| Q35747147 | A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23 |
| Q56436562 | A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3 |
| Q28943522 | A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus |
| Q29417084 | A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. |
| Q29417036 | A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. |
| Q33780746 | A genome-wide association study of prognosis in breast cancer |
| Q70989153 | A golden jubilee |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q34433744 | A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants |
| Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
| Q35248192 | A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer |
| Q36435849 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. |
| Q46319161 | A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival. |
| Q36409909 | A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities |
| Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
| Q35699278 | A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma |
| Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
| Q83523872 | A population-based validation of the prognostic model PREDICT for early breast cancer |
| Q59182615 | A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma |
| Q78878913 | A prospective study of tea drinking temperature and risk of esophageal squamous cell carcinoma |
| Q72399204 | A randomized controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis |
| Q45984038 | A review of the online prognositc model predict using the POSH cohort (women aged ≤40 years at breast cancer diagnosis). |
| Q37599352 | A role for XRCC2 gene polymorphisms in breast cancer risk and survival |
| Q30276359 | A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer |
| Q74688260 | A systematic review and meta-analysis of family history and risk of ovarian cancer |
| Q33766628 | A systematic review of genetic polymorphisms and breast cancer risk. |
| Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
| Q91677080 | A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants |
| Q44443237 | A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. |
| Q34854883 | A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer |
| Q36327057 | ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium |
| Q114370608 | Abstract 303: Cell Slider: Using crowd sourcing for the scoring of molecular pathology |
| Q24609281 | Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study |
| Q36387794 | Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials |
| Q38406780 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study |
| Q52647897 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. |
| Q83941826 | Advocacy strategies and action plans for reducing salt intake in Iran |
| Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Q57175538 | Alcohol consumption and future hospital usage: The EPIC-Norfolk prospective population study |
| Q30779634 | Alcohol consumption and survival after a breast cancer diagnosis: a literature-based meta-analysis and collaborative analysis of data for 29,239 cases |
| Q46586463 | Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer |
| Q73591212 | An analysis of ovarian tumor diameter and survival |
| Q35198352 | An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ⩽40 years at breast cancer diagnosis |
| Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
| Q33716808 | An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation |
| Q42371458 | Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci |
| Q36831854 | Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome |
| Q35681656 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis |
| Q85771787 | Any conclusion from this "citizens' jury" will be seriously flawed |
| Q43216352 | Apnoea monitoring at home |
| Q73704841 | Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing |
| Q34613673 | Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study |
| Q30276986 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes |
| Q30277151 | Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors |
| Q33781177 | Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies |
| Q90666760 | Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium |
| Q97070156 | Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers |
| Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
| Q37684409 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer |
| Q91397549 | Association Between Levels of Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus |
| Q64056497 | Association analyses identify 31 new risk loci for colorectal cancer susceptibility |
| Q57305944 | Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q27851709 | Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer |
| Q44817903 | Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients |
| Q84635142 | Association between KRAS rs61764370 and triple-negative breast cancer--a false positive? |
| Q33828680 | Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival |
| Q33471495 | Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer |
| Q33279162 | Association between common variation in 120 candidate genes and breast cancer risk |
| Q37200998 | Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study |
| Q37151872 | Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. |
| Q41695706 | Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer |
| Q37292963 | Association of ESR1 gene tagging SNPs with breast cancer risk |
| Q46707380 | Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis |
| Q45188733 | Association of a common variant of the CASP8 gene with reduced risk of breast cancer |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
| Q114182713 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment |
| Q56337548 | Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study |
| Q36593602 | Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population |
| Q57306187 | Association of the Progesterone Receptor Gene with Breast Cancer Risk: A Single-Nucleotide Polymorphism Tagging Approach |
| Q39423088 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study |
| Q35934138 | Association studies for finding cancer-susceptibility genetic variants |
| Q37151879 | Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer |
| Q119213340 | Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
| Q36671817 | Astronomical algorithms for automated analysis of tissue protein expression in breast cancer |
| Q36792641 | Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation |
| Q36001510 | Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer |
| Q63966080 | Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci |
| Q64118820 | Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci |
| Q60917552 | Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility |
| Q60912720 | Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma |
| Q92904333 | Authors' response: Associations of obesity and circulating insulin and glucose with breast cancer risk |
| Q24531993 | Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies |
| Q24610409 | BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received |
| Q45943885 | BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. |
| Q91045517 | BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors |
| Q77495310 | BRCA1 and BRCA2 mutations in Russian familial breast cancer |
| Q24803673 | BRCA1 and BRCA2 mutations in a population-based study of male breast cancer |
| Q40261707 | BRCA1 suppresses osteopontin-mediated breast cancer |
| Q57266729 | BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives |
| Q59689002 | BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q57306056 | BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk |
| Q64018977 | Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index |
| Q70811494 | Bed-sharing and sudden infant death |
| Q38405561 | Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue |
| Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
| Q92720845 | Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk |
| Q100457582 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk |
| Q43073201 | Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies |
| Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
| Q102073773 | Breast cancer risk factors and their effects on survival: a Mendelian randomisation study |
| Q36973531 | Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q44937823 | Breast cancer risks for BRCA1/2 carriers |
| Q35562912 | Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study |
| Q34158093 | Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression |
| Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
| Q33630773 | COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. |
| Q36419325 | CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer |
| Q34180983 | CYP2D6 gene variants and their association with breast cancer susceptibility |
| Q21195205 | CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen |
| Q92005489 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families |
| Q99569177 | Cancer Screening, Surrogates of Survival, and the Soma |
| Q36871595 | Cancer genetics of epigenetic genes |
| Q35889609 | Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance |
| Q101237548 | Cancer therapy shapes the fitness landscape of clonal hematopoiesis |
| Q37344880 | Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk |
| Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q28385765 | Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk |
| Q49181021 | Cardiovascular disease mortality and years of life lost attributable to non-optimal systolic blood pressure and hypertension in northeastern Iran. |
| Q48661059 | Catastrophic failures of public health. |
| Q36869180 | Cell type-specific DNA methylation patterns in the human breast |
| Q35693892 | Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci |
| Q37282647 | Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies |
| Q30275068 | Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies |
| Q98905585 | Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses |
| Q35782435 | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer |
| Q57250578 | ClinGen and Genetic Testing |
| Q96576896 | Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium |
| Q28307436 | Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status |
| Q95604482 | Collateral damage: the impact on cancer outcomes of the COVID-19 pandemic |
| Q95637487 | Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic |
| Q37657957 | Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer |
| Q94486442 | Combined associations of a polygenic risk score and classical risk factors with breast cancer risk |
| Q33627208 | Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients |
| Q34720998 | Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier |
| Q91013280 | Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. |
| Q91579538 | Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma |
| Q24797594 | Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study |
| Q35668946 | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk |
| Q38671007 | Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions |
| Q36490507 | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). |
| Q57265809 | Common Polymorphisms in ERCC2 (Xeroderma pigmentosum D) are not Associated with Breast Cancer Risk |
| Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34126314 | Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer |
| Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
| Q36856357 | Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls |
| Q36898448 | Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity |
| Q24658131 | Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer |
| Q33794903 | Common germ-line polymorphism of C1QA and breast cancer survival |
| Q34651737 | Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q45263043 | Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer |
| Q59654812 | Common germline variation in mismatch repair genes and survival after a diagnosis of colorectal cancer |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q73806219 | Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk |
| Q28237788 | Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival |
| Q46209474 | Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk |
| Q98390794 | Common susceptibility loci for male breast cancer |
| Q29417145 | Common variants at 19p13 are associated with susceptibility to ovarian cancer |
| Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q36255665 | Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer |
| Q41852502 | Common variants in WFS1 confer risk of type 2 diabetes |
| Q115209587 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes |
| Q57306185 | Common variants in mismatch repair genes and risk of colorectal cancer |
| Q53345077 | Common variants in mismatch repair genes and risk of invasive ovarian cancer. |
| Q35794359 | Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk |
| Q21260438 | Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs |
| Q29417133 | Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk |
| Q96353887 | Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe) |
| Q44922577 | Comparative trends in cause-specific fetal and neonatal mortality in twin and singleton births in the North of England, 1982-1994. |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q33803680 | Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer |
| Q36026731 | Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer |
| Q36584124 | Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q37155532 | Consortium analysis of 7 candidate SNPs for ovarian cancer |
| Q34342248 | Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk |
| Q28266112 | Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population |
| Q59688934 | Contribution ofBRCA1andBRCA2mutations to inherited ovarian cancer |
| Q91763335 | Correction: BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q57565042 | Corrigendum re “Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma” [Eur Urol 2017;72:747–54] |
| Q94323291 | Cost effectiveness of lowering cholesterol |
| Q36598749 | Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population |
| Q36831219 | Cost effectiveness of the NHS breast screening programme: life table model |
| Q57177092 | Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model |
| Q48526678 | Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. |
| Q37533025 | Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer |
| Q28388475 | Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations |
| Q30660858 | Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer |
| Q92184158 | Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer |
| Q37409157 | Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals |
| Q40262024 | Dairy Food Intake and All-Cause, Cardiovascular Disease, and Cancer Mortality: The Golestan Cohort Study |
| Q36967608 | Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays |
| Q30666763 | Degenerate oligonucleotide primed-polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers : a new approach for the molecular analysis of paraffin-embedded cancer tissue |
| Q28658745 | Determinants of gastroesophageal reflux disease, including hookah smoking and opium use- a cross-sectional analysis of 50,000 individuals |
| Q47298550 | Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants |
| Q52695031 | Development and External Validation of Prediction Models for 10-Year Survival of Invasive Breast Cancer. Comparison with PREDICT and CancerMath. |
| Q96590073 | Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) |
| Q40662836 | Development of a protocol for evaluation of mammographic surveillance services in women under 50 with a family history of breast cancer |
| Q34067025 | Diabetes mellitus and its correlates in an Iranian adult population |
| Q39008217 | Dietary Protein Sources and All-Cause and Cause-Specific Mortality: The Golestan Cohort Study in Iran |
| Q35781238 | Dietary intake of minerals and risk of esophageal squamous cell carcinoma: results from the Golestan Cohort Study |
| Q60472142 | Discovery of common and rare genetic risk variants for colorectal cancer |
| Q28084601 | Do Health Professionals Need Additional Competencies for Stratified Cancer Prevention Based on Genetic Risk Profiling? |
| Q27851413 | Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium |
| Q43924266 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. |
| Q92342048 | Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups |
| Q55110745 | E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. |
| Q33824208 | ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study |
| Q42756655 | Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate |
| Q48086557 | Educating doctors and patients about how conflicts of interest can affect healthcare decision making |
| Q36724762 | Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival |
| Q36787362 | Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort |
| Q72288303 | Endemic goitre and cretinism in the Simbai and Tep-Tep areas of Madang Province, Papua New Guinea |
| Q34778269 | Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study |
| Q38720533 | Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci |
| Q24633316 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer |
| Q36487146 | Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk |
| Q57083824 | Erratum: COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer |
| Q57250672 | Erratum: Corrigendum: A common coding variant in CASP8 is associated with breast cancer risk |
| Q57319395 | Erratum: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer |
| Q42737815 | Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes |
| Q57306046 | Erratum: Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer Association Consortium |
| Q36682611 | Erythromelalgia--the role of hypnotherapy |
| Q33932856 | Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium |
| Q51766497 | Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. |
| Q60487429 | European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer |
| Q98184153 | European polygenic risk score for prediction of breast cancer shows similar performance in Asian women |
| Q36966218 | Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study |
| Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
| Q51955474 | Evaluation of an algorithm of tagging SNPs selection by linkage disequilibrium. |
| Q91549968 | Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk |
| Q21144976 | Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot" |
| Q57172770 | Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study |
| Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
| Q64110801 | Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women |
| Q34687073 | Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study |
| Q74157664 | Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study |
| Q90183296 | Evidence of a Causal Association Between Cancer and Alzheimer's Disease: a Mendelian Randomization Analysis |
| Q36067788 | Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis |
| Q36720821 | Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors |
| Q38475420 | Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q38845261 | Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk |
| Q98241943 | Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies |
| Q34430369 | Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types |
| Q37323340 | FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation |
| Q30443024 | Familial gastric cancer: overview and guidelines for management |
| Q73670879 | Familial predisposition to breast cancer in a British population: implications for prevention |
| Q33892928 | Familial relative risks for breast cancer by pathological subtype: a population-based cohort study |
| Q41495151 | Family history and the risk of breast cancer: a systematic review and meta-analysis |
| Q42151643 | Fetal loss, gravidity, and pregnancy order |
| Q35083710 | Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions |
| Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
| Q33878276 | Fine scale mapping of the breast cancer 16q12 locus |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q36087170 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
| Q36856343 | Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression |
| Q55380382 | Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q55311842 | Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. |
| Q35063160 | Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk |
| Q35097143 | Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q37002930 | Five endometrial cancer risk loci identified through genome-wide association analysis |
| Q25256652 | Five glutathione s-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies |
| Q34979715 | Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium |
| Q50680047 | Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. |
| Q59689039 | Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers |
| Q46943059 | From association to cause: fine mapping of the TNRC9 gene region, a novel susceptibility locus identified in the first genome-wide association study for breast cancer. |
| Q91016919 | Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. |
| Q114182808 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element |
| Q34958831 | Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival |
| Q90618446 | Functional informed genome-wide interaction analysis of body mass index, diabetes and colorectal cancer risk |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q34031757 | Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q36956156 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer |
| Q38408978 | GWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer |
| Q35815416 | Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes |
| Q40137431 | Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium |
| Q36175072 | Gene-panel sequencing and the prediction of breast-cancer risk |
| Q62583319 | Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk |
| Q37389405 | Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer |
| Q39200248 | Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma |
| Q115209620 | Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus |
| Q81462241 | Genetic epidemiology of cancer: relatively risky relatives |
| Q50062417 | Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. |
| Q108609948 | Genetic insights into biological mechanisms governing human ovarian ageing |
| Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
| Q54940815 | Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. |
| Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q62583135 | Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma |
| Q35194233 | Genetic susceptibility, predicting risk and preventing cancer. |
| Q63976721 | Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer |
| Q28481918 | Genetic variants in ER cofactor genes and endometrial cancer risk |
| Q34497690 | Genetic variants in epigenetic genes and breast cancer risk. |
| Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34038369 | Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis |
| Q34453723 | Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium |
| Q34955369 | Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q37131328 | Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies |
| Q24811147 | Genetic variation in the HSD17B1 gene and risk of prostate cancer |
| Q37311599 | Genetic variation in the chromosome 17q23 amplicon and breast cancer risk |
| Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
| Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
| Q92387949 | Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent |
| Q103024151 | Genetically predicted circulating protein biomarkers and ovarian cancer risk |
| Q46023963 | Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease. |
| Q55053559 | Genetics: How to validate a breast cancer prognostic signature. |
| Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
| Q36218993 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium |
| Q98216310 | Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q93270780 | Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility |
| Q37422744 | Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q92534414 | Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women |
| Q34537405 | Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis |
| Q37202841 | Genome-wide association study for ovarian cancer susceptibility using pooled DNA. |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q29417135 | Genome-wide association study identifies a common variant associated with risk of endometrial cancer |
| Q29417050 | Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk |
| Q34114293 | Genome-wide association study identifies five new breast cancer susceptibility loci |
| Q33804470 | Genome-wide association study identifies multiple risk loci for renal cell carcinoma |
| Q24645441 | Genome-wide association study identifies novel breast cancer susceptibility loci |
| Q52720511 | Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. |
| Q59795648 | Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma |
| Q47125417 | Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q38970751 | Genome-wide association study of prostate cancer-specific survival |
| Q28943264 | Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3 |
| Q33778612 | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. |
| Q36019187 | Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma |
| Q59566871 | Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility |
| Q38823212 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk |
| Q47552886 | Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study |
| Q96432094 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk |
| Q36276527 | Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer |
| Q81419376 | Germline genetic variation and breast cancer survival: prognostic and therapeutic implications |
| Q35114576 | Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer |
| Q54994597 | Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. |
| Q36916243 | Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer |
| Q114182677 | Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis |
| Q39530717 | Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma |
| Q40053289 | Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene |
| Q91931549 | Going to extremes: determinants of extraordinary response and survival in patients with cancer |
| Q34014453 | HSD17B1 genetic variants and hormone receptor-defined breast cancer |
| Q36612585 | HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer |
| Q37484235 | Haplotypes of the estrogen receptor beta gene and breast cancer risk |
| Q42576907 | Health promotion in general practice. Health promotion contributes to the battle against heart disease. |
| Q71783620 | Health promotion in primary care: modelling the impact of intervention on coronary heart disease and stroke |
| Q36032847 | Heart Disease Is Associated With Anthropometric Indices and Change in Body Size Perception Over the Life Course: The Golestan Cohort Study |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q38647896 | Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium |
| Q62583666 | Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium |
| Q44588813 | Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma |
| Q41579926 | Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond |
| Q33330850 | Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics |
| Q36547888 | Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers |
| Q37121271 | High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium |
| Q33551425 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study |
| Q50121421 | Hospital outbreak of Salmonella virchow possibly associated with a food handler. |
| Q28397073 | Household Fuel Use and Cardiovascular Disease Mortality: Golestan Cohort Study |
| Q96831791 | Household Fuel Use and the Risk of Gastrointestinal Cancers: The Golestan Cohort Study |
| Q51921928 | How not to interpret a P value? |
| Q28303249 | Hyaluronan-mediated motility receptor gene single nucleotide polymorphisms and risk of breast cancer |
| Q41679377 | Hypertension and mortality in the Golestan Cohort Study: A prospective study of 50 000 adults in Iran |
| Q57202722 | IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q37006170 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. |
| Q38331174 | Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays |
| Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
| Q29417155 | Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array |
| Q91889338 | Identification of Novel Loci and New Risk Variant in Known Loci for Colorectal Cancer Risk in East Asians |
| Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
| Q112717190 | Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer |
| Q34975918 | Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript |
| Q24653491 | Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q58743933 | Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma |
| Q34038964 | Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions |
| Q57170142 | Identification of nine new susceptibility loci for endometrial cancer |
| Q90091185 | Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants |
| Q93009462 | Identification of novel epithelial ovarian cancer loci in women of African ancestry |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q100568879 | Identifying novel susceptibility genes for colorectal cancer risk from a transcriptome-wide association study of 125,478 subjects |
| Q43819639 | Impact of body size and physical activity during adolescence and adult life on overall and cause-specific mortality in a large cohort study from Iran |
| Q26825771 | Implementing risk-stratified screening for common cancers: a review of potential ethical, legal and social issues |
| Q35602297 | Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis |
| Q36955208 | Implications of using whole genome sequencing to test unselected populations for high risk breast cancer genes: a modelling study |
| Q45243999 | Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families |
| Q34694845 | Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer |
| Q37614763 | Incorporating genomics into breast and prostate cancer screening: assessing the implications |
| Q114184688 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model |
| Q37378034 | Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model |
| Q59689071 | Increased frequency ofTP53 mutations inBRCA1 andBRCA2 ovarian tumours |
| Q34240634 | Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study |
| Q64105020 | Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model |
| Q35830446 | Influence of Spirituality and Modesty on Acceptance of Self-Sampling for Cervical Cancer Screening |
| Q38131236 | Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning? |
| Q37684424 | Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration |
| Q34575290 | Inherited variants in regulatory T cell genes and outcome of ovarian cancer |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q30275132 | Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci |
| Q52649946 | Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. |
| Q24652651 | Interactions between genes involved in the antioxidant defence system and breast cancer risk |
| Q57987295 | Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma |
| Q30277784 | Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer |
| Q34898735 | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors |
| Q35425010 | Issues of consent and feedback in a genetic epidemiological study of women with breast cancer |
| Q59487374 | It's PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence |
| Q47190168 | Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium |
| Q37397635 | Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancer |
| Q41752374 | LIFETIME RISK OF OVARIAN CANCER BASED ON ENDOMETRIOSIS AND OTHER RISK FACTORS: IGCS-0014 06. Ovarian Cancer |
| Q35022313 | LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer |
| Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
| Q37725393 | Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome |
| Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q43936170 | Long-term erectile function following permanent seed brachytherapy treatment for localized prostate cancer |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q48566091 | Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. |
| Q43610892 | Mammographic screening in women with a family history of breast cancer: some results from the Swedish two-county trial |
| Q46483244 | Maternal thyroid function and motor competence in the child |
| Q37160706 | Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening |
| Q89685277 | Mendelian Randomization of Circulating Polyunsaturated Fatty Acids and Colorectal Cancer Risk |
| Q56089167 | Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer |
| Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
| Q93370418 | Mendelian randomization analysis of C-reactive protein on colorectal cancer risk |
| Q97528612 | Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival |
| Q33338630 | Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer |
| Q34091855 | Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development |
| Q37283218 | Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer |
| Q29417081 | Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer |
| Q36333368 | Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. |
| Q29417032 | Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33 |
| Q63352621 | Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci |
| Q35156802 | MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q41705634 | Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients |
| Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
| Q44894734 | Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening |
| Q92962785 | Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review |
| Q37401549 | Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival |
| Q30765398 | Molecular classification of breast carcinomas using tissue microarrays |
| Q79222321 | Molecular genetics and the assessment of human cancers |
| Q24598972 | Molecular pathology in epidemiologic studies: a primer on key considerations |
| Q48526528 | Money is the greatest conflict of all. |
| Q39155379 | Mortality from respiratory diseases associated with opium use: a population-based cohort study |
| Q34736858 | Most common 'sporadic' cancers have a significant germline genetic component |
| Q112709172 | Multi-omic machine learning predictor of breast cancer therapy response |
| Q21144952 | Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q33988405 | Multiple loci with different cancer specificities within the 8q24 gene desert |
| Q35646703 | Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans |
| Q52675313 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. |
| Q44122371 | Neither off the peg nor made to measure calculations are fit for purpose |
| Q26799669 | Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk |
| Q37398841 | New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q64458449 | No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study |
| Q30275832 | No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival |
| Q35061078 | No association between SNPs regulating TGF-β1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study |
| Q33982873 | No association between TERT-CLPTM1L single nucleotide polymorphism rs401681 and mean telomere length or cancer risk |
| Q36292769 | No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer |
| Q53417363 | No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
| Q37162103 | Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype |
| Q35752042 | Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures |
| Q56359054 | Novel Common Genetic Susceptibility Loci for Colorectal Cancer |
| Q47273706 | Opium Use and Risk of Pancreatic Cancer: A Prospective Cohort Study |
| Q35894600 | Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran |
| Q46026083 | Opium use and risk of mortality from digestive diseases: a prospective cohort study. |
| Q94469362 | Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study |
| Q36696565 | Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations |
| Q57225792 | Outcome of pregnancies following the use of oral contraceptives |
| Q86549176 | Outside the Box: Proactive care: the patient's right to choose |
| Q99569164 | Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites |
| Q89927576 | Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D |
| Q35802988 | Ovarian cancer risk associated with inherited inflammation-related variants |
| Q59689022 | Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations |
| Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q91087734 | Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom-Reply |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q41035618 | PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes |
| Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
| Q37353838 | PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations |
| Q36184231 | PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. |
| Q24600928 | PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer |
| Q46826597 | PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression |
| Q34289136 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche |
| Q112572520 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes |
| Q35741630 | Pathology of ovarian cancers in BRCA1 and BRCA2 carriers |
| Q34627936 | Patient and tumour characteristics, management, and age-specific survival in women with breast cancer in the East of England |
| Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
| Q36574725 | Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity |
| Q36222126 | Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study |
| Q36873786 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium |
| Q96577047 | Personalized early detection and prevention of breast cancer: ENVISION consensus statement |
| Q37333975 | Personalized screening for cancers: should we consider polygenic profiling? |
| Q61970259 | Personalized testing based on polygenic risk score is promising for more efficient population-based screening programs for common oncological diseases |
| Q36671536 | Pharmacogenetics of cancer chemotherapy |
| Q89454638 | Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis |
| Q81523323 | Polygenes, risk prediction, and targeted prevention of breast cancer |
| Q57306194 | Polygenic Inherited Predisposition to Breast Cancer |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q47561710 | Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts |
| Q92150059 | Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study |
| Q78029012 | Polygenic susceptibility to breast cancer and implications for prevention |
| Q37062641 | Polygenic susceptibility to breast cancer: current state-of-the-art |
| Q34977428 | Polygenic susceptibility to prostate and breast cancer: implications for personalised screening |
| Q33891803 | Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium |
| Q24648412 | Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women |
| Q44938215 | Polymorphisms associated with circulating sex hormone levels in postmenopausal women |
| Q43792195 | Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk |
| Q33361584 | Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium |
| Q60895659 | Polymorphisms in RET and Its Coreceptors and Ligands as Genetic Modifiers of Multiple Endocrine Neoplasia Type 2A |
| Q36915870 | Polymorphisms in inflammation pathway genes and endometrial cancer risk |
| Q33921008 | Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium |
| Q53414081 | Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. |
| Q40386919 | Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma |
| Q36966258 | Population distribution of lifetime risk of ovarian cancer in the United States |
| Q37513339 | Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps |
| Q36233914 | Population-based screening in the era of genomics |
| Q96431220 | Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer |
| Q57162797 | Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival |
| Q31152672 | Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics |
| Q92055460 | Prediction and clinical utility of a contralateral breast cancer risk model |
| Q37487782 | Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q91832507 | Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts |
| Q41584352 | Prediction of individual genetic risk to prostate cancer using a polygenic score |
| Q57266776 | Prediction of pathogenic mutations in patients with early-onset breast cancer by family history |
| Q38347216 | Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). |
| Q37154445 | Prevalence, awareness and risk factors of hypertension in a large cohort of Iranian adult population |
| Q37225727 | Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? |
| Q36614790 | Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis |
| Q59391975 | Prognosis by breast cancer subtypes in patients treated with adjuvant chemotherapy in a clinical trial |
| Q42435532 | Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial |
| Q96027123 | Prognostic gene expression signature for high-grade serous ovarian cancer |
| Q37318149 | Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression |
| Q37350137 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups |
| Q37153948 | Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients |
| Q35223068 | Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer |
| Q34811135 | Public health genomics and personalized prevention: lessons from the COGS project |
| Q86499074 | Public health implications from COGS and potential for risk stratification and screening |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q96816951 | Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement |
| Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q57306176 | RAPPER: The Radiogenomics of Radiation Toxicity |
| Q89458655 | RE: Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data |
| Q57306197 | RESPONSE: Re: Polymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women |
| Q64108927 | Radiogenomics Consortium Genome-Wide Association Study Meta-analysis of Late Toxicity after Prostate Cancer Radiotherapy |
| Q30833608 | Radiogenomics: radiobiology enters the era of big data and team science |
| Q51102391 | Rare germline copy number deletions of likely functional importance are implicated in endometrial cancer predisposition. |
| Q114182625 | Rare germline copy number variants (CNVs) and breast cancer risk |
| Q35741115 | Rat Mcs5a is a compound quantitative trait locus with orthologous human loci that associate with breast cancer risk |
| Q53126224 | Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patien |
| Q45151860 | Re: On the use of familial aggregation in population-based case probands for calculating penetrance |
| Q82893817 | Re: promoting healthy skepticism in the news: helping journalists get it right |
| Q83367286 | Reducing salt intake in Iran: priorities and challenges |
| Q98158747 | Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q35688605 | Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13 |
| Q36336182 | Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis |
| Q85509167 | Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--response |
| Q94346063 | Reply: Remarks on the BOADICEA model of genetic susceptibility to breast and ovarian Cancer Research UK |
| Q46598623 | Reply: a bias in genotyping of the ERBB2 (HER2) Ile655Val variant |
| Q45951126 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. |
| Q37393598 | Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing" |
| Q26780387 | Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer |
| Q35815958 | Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci |
| Q44115162 | Risk factors for breast cancer: a reanalysis of two case-control studies from 1926 and 1931. |
| Q43428196 | Risk factors for the incidence of breast cancer: do they affect survival from the disease? |
| Q51567938 | Risk illiteracy rides again. Balancing probabilities. |
| Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
| Q37624504 | Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10 |
| Q38716934 | Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence |
| Q46776482 | Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers |
| Q37453871 | Role of genetic polymorphisms and ovarian cancer susceptibility |
| Q37188838 | Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium |
| Q48593779 | Role of gonadal and adrenal steroids in the impairment of the male rat's sexual behaviour by hyperprolactinaemia. |
| Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
| Q45091978 | STK15 polymorphisms and association with risk of invasive ovarian cancer. |
| Q48317334 | Science is like a vast jigsaw |
| Q33657349 | Screening for breast and ovarian cancer: the relevance of family history |
| Q35596203 | Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests. |
| Q50105509 | Selective or universal neonatal BCG immunization: what policy for a district with a high incidence of tuberculosis? |
| Q33467087 | Seq4SNPs: new software for retrieval of multiple, accurately annotated DNA sequences, ready formatted for SNP assay design |
| Q29417074 | Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study |
| Q92969786 | Sex specific associations in genome wide association analysis of renal cell carcinoma |
| Q99370922 | Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma |
| Q36089391 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer |
| Q61118451 | Shared heritability and functional enrichment across six solid cancers |
| Q64004349 | Shared heritability and functional enrichment across six solid cancers |
| Q42437946 | Shedding light on skin cancer |
| Q51347290 | Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases. |
| Q33396252 | Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults |
| Q37151786 | Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer |
| Q36614423 | Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British population |
| Q33222808 | Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. |
| Q30582591 | Smoking water-pipe, chewing nass and prevalence of heart disease: a cross-sectional analysis of baseline data from the Golestan Cohort Study, Iran |
| Q57954085 | Society for Social Medicine and the International Epidemiological Association European Group. Abstracts of oral presentations |
| Q36620640 | Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis |
| Q36835706 | Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer |
| Q37248410 | Stage shift in PSA-detected prostate cancers - effect modification by Gleason score |
| Q33909674 | Standardized Total Average Toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies |
| Q38077865 | Stratified cancer screening: the practicalities of implementation |
| Q33593016 | Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies |
| Q74462145 | Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group |
| Q35038651 | TGF-β signaling pathway and breast cancer susceptibility |
| Q42512528 | TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer |
| Q33566957 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer |
| Q50690518 | Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. |
| Q33277172 | Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer |
| Q34486210 | Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer |
| Q37141940 | Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer |
| Q91044035 | Targeted Resequencing of the Coding Sequence of 38 Genes Near Breast Cancer GWAS Loci in a Large Case-Control Study |
| Q33794700 | Telomere length in prospective and retrospective cancer case-control studies |
| Q28397509 | Telomere structure and maintenance gene variants and risk of five cancer types |
| Q55564651 | Textbook of community medicine in South-East Asia. |
| Q36615665 | The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions |
| Q45973022 | The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. |
| Q36921422 | The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin |
| Q33300099 | The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study |
| Q39187031 | The Combined Effects of Healthy Lifestyle Behaviors on All-Cause Mortality: The Golestan Cohort Study. |
| Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
| Q52673733 | The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. |
| Q37578078 | The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers |
| Q28552519 | The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study |
| Q57306198 | The Reliable Identification of Disease-Gene Associations |
| Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
| Q56772366 | The US Office for Human Research Protections' judgment of the SUPPORT trial seems entirely reasonable |
| Q34759322 | The admixture maximum likelihood test to test for association between rare variants and disease phenotypes |
| Q80298785 | The admixture maximum likelihood test: a novel experiment-wise test of association between disease and multiple SNPs |
| Q62583294 | The association between low-density lipoprotein cholesterol predicted by HMGCR genetic variants and breast cancer risk may be mediated by body mass index |
| Q50709318 | The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. |
| Q60487433 | The association between weight at birth and breast cancer risk revisited using Mendelian randomisation |
| Q64239462 | The association between weight at birth and breast cancer risk revisited using Mendelian randomisation |
| Q94548558 | The challenge of early detection in cancer |
| Q35642140 | The clinical performance of an office-based risk scoring system for fatal cardiovascular diseases in North-East of Iran |
| Q29619914 | The clonal and mutational evolution spectrum of primary triple-negative breast cancers |
| Q33991747 | The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population |
| Q57225638 | The effect of age and gravidity on menstruation |
| Q35608194 | The effect of rare variants on inflation of the test statistics in case-control analyses |
| Q96230855 | The effect of sample size on polygenic hazard models for prostate cancer |
| Q34333988 | The effect on melanoma risk of genes previously associated with telomere length |
| Q57694684 | The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators |
| Q64998464 | The functional ALDH2 polymorphism is associated with breast cancer risk: A pooled analysis from the Breast Cancer Association Consortium. |
| Q26999319 | The gastro-esophageal malignancies in Northern Iran research project: impact on the health research and health care systems in Iran |
| Q33923794 | The genetics of inherited breast cancer |
| Q34987593 | The genetics of ovarian cancer |
| Q55445982 | The importance of using public data to validate reported associations. |
| Q34775177 | The inherited genetics of ovarian and endometrial cancer |
| Q36347067 | The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape |
| Q54796500 | The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk. |
| Q38006386 | The potential for risk stratification in the management of ovarian cancer risk |
| Q64018926 | The prognostic significance of lymphovascular invasion in invasive breast carcinoma |
| Q35024008 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q46364450 | The search for low-penetrance breast cancer genes. |
| Q28275430 | The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes |
| Q71359394 | The toxic effect of language on medicine |
| Q34151528 | Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q42697902 | Translating genomics into improved population screening: hype or hope? |
| Q57259509 | Tu1941 Opium Use and Risk of Pancreatic Cancer: A Prospective Cohort Study |
| Q57542900 | Turning the Pump Handle: Evolving Methods for Integrating the Evidence on Gene-Disease Association |
| Q39353656 | Two cases of cutaneous leishmaniasis in Malawi |
| Q92994868 | Two truncating variants in FANCC and breast cancer risk |
| Q115601277 | Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry |
| Q90114858 | Understanding of prognosis in non-metastatic prostate cancer: a randomised comparative study of clinician estimates measured against the PREDICT prostate prognostic model |
| Q50084544 | Use of deep whole genome sequencing data to identify structure risk variants in breast cancer susceptibility genes. |
| Q94584958 | Usual physical activity and subsequent hospital usage over 20 years in a general population: the EPIC-Norfolk cohort |
| Q37081074 | Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium |
| Q55386463 | Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. |
| Q47444714 | Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population |
| Q34129771 | Variants in DNA double-strand break repair genes and breast cancer susceptibility |
| Q56342454 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility |
| Q33847791 | Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer |
| Q33636005 | Variation in genes required for normal mitosis and risk of breast cancer |
| Q34054318 | Variation in prescribing of hypnotics, anxiolytics and antidepressants between 61 general practices. |
| Q57306045 | Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival |
| Q33612282 | Verbal autopsy: reliability and validity estimates for causes of death in the Golestan Cohort Study in Iran |
| Q42834204 | Vitamin A supplementation in preschool children with acute diarrhoea. |
| Q34274328 | Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium |
| Q43530466 | Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival |
| Q39458551 | What ethical and legal principles should guide the genotyping of children as part of a personalised screening programme for common cancer? |
| Q83985246 | Why the victims were silent |
| Q122925830 | p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study |
| Q37376012 | p53 polymorphisms: cancer implications |
| Q56334023 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology |
Search more.